Loading
Laser / Fractional / Amyloid · Interventional Study
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed small randomized controlled trial comparing fractional CO₂ laser treatment to control in primary cutaneous amyloidosis, with results not yet posted in this registry record. The study assessed change in Amyloidosis Severity Score as primary outcome, with secondary evaluations of imaging, ultrastructure, symptoms, and safety. No efficacy or safety data are available from this registry entry.
Interventional, Randomized, Parallel, Single masking, Treatment purpose. Amyloid, Fractional, Laser; age from 18 Years. Intervention: Fractional CO₂ Laser. Compared with: Control — No Intervention. n = 22. 1 site: Egypt.
This is a completed small randomized controlled trial comparing fractional CO₂ laser treatment to control in primary cutaneous amyloidosis, with results not yet posted in this registry record. The study assessed change in Amyloidosis Severity Score as primary outcome, with secondary evaluations of imaging, ultrastructure, symptoms, and safety. No efficacy or safety data are available from this registry entry.
Results are not posted in this registry record; efficacy, safety, and comparative effectiveness cannot be assessed from the entry provided
The source did not state who this applies to in practice.
Small randomized controlled trial with completed enrollment but no results posted; design is sound but sample size is modest and outcome is a disease-specific severity score rather than a validated clinical endpoint.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07815132). This is a study registration, not published results. Lead sponsor: Tanta University. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 22 participants (ACTUAL). Conditions: Amyloid, Fractional, Laser. Interventions: DEVICE: Fractional CO₂ Laser. Primary outcome measures: Amyloidosis Severity Score , Baseline to 1 month after the last treatment session (Week 12). Brief summary: This randomized, controlled clinical study will evaluate the clinical and ultrastructural effects, efficacy, and safety of fractional CO₂ laser in patients with primary cutaneous amyloidosis. Twenty-two eligible patients will be randomly allocated in a 1:1 ratio to receive either three fractional CO₂ laser sessions at 4-week intervals or no active laser treatment (control group). The primary outcome will be the change in the Amyloidosis Severity Score from baseline to one month after the final laser session, with secondary assessments including dermoscopic findings, transmission electron microscopy findings, pruritus severity, patient satisfaction, and adverse events.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.